• 1.

    Heerspink HJL, et al.. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Legendre CM, et al.. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:21692181. doi: 10.1056/NEJMoa1208981

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Vincenti F, et al.. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333343. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med 2016; 374:698.

    • Crossref
    • Search Google Scholar
    • Export Citation

Acquiring Novel Agents for Kidney Disease in India: A Pipe Dream or Science Fiction?

  • 1 Mayuri Trivedi, DM, is Assistant Professor, Nephrology Services, Department of Medicine, LTMGH, and consultant nephrologist and transplant physician, Hinduja Healthcare Surgical and S L Raheja Fortis Hospital, Mumbai, India.
Restricted access
Save